Amjevita (adalimumab-atto) is a prescription drug used for certain inflammatory conditions, including rheumatoid arthritis and ulcerative colitis. Amjevita can cause side effects that range from mild ...

Since the late 1990s, multiple biologic drugs have been approved to help people with ulcerative colitis (UC) and Crohn’s disease achieve and maintain remission. This includes biosimilars, which are ...

The biosimilar Hyrimoz showed similar flare rates to Humira, but 25% of patients experienced adverse events, mainly injection site reactions. Injection pain, linked to Hyrimoz's citrate content and ...

Non-infectious uveitis is a rare immune-mediated condition in children and is often treated with the tumor necrosis factor inhibitor adalimumab. Discontinuing the drug may be considered when remission ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — Patients in early rheumatoid arthritis respond well to either abatacept or adalimumab, with the ...

Discontinuing adalimumab increases relapse rates in patients with juvenile idiopathic arthritis (JIA)–associated uveitis. However, patients can regain inflammation control after resuming the treatment ...

In people with psoriasis taking adalimumab, there was no significant difference between adalimumab monotherapy and adalimumab with concomitant methotrexate, according to a recent report in JAMA ...

Patients with noninfectious intermediate, posterior, or panuveitis requiring immunosuppressive therapy while on prednisone were more likely to have their corticosteroid dose reduced or systemic ...